menu ☰
menu ˟

Long-term treatment with baricitinib well tolerated for active RA

02 Oct 2018
Despite an elevated infection risk, particularly for herpes zoster, baricitinib was generally well tolerated among patients with moderate to severe active rheumatoid arthritis with exposure of up to 5.5 years, according to findings published in the J...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.